Received Mar 4, 2025
| Type | Name | Manufacturer | Dose | Lot | Route / Site |
|---|---|---|---|---|---|
| TYP | TYPHOID LIVE ORAL TY21A (VIVOTIF) | BERNA BIOTECH, LTD. | 3 | Unknown | PO / MO |
Patient had tested positive to COVID and had some mild congestion, cough and no other symptoms; Case reference number US-BN-2024-001786 is a spontaneous case report initially received from a nurse via Med Communication (reference number: USBAV24-0707) on 10-Apr-2024 and concerns a 54-year-old male patient. The patient's medical history and concomitant medication details were not provided. On 05-Apr-2024, the patient took the first dose of Vivotif (batch number: unknown) at an unknown dose, via oral use for immunization against disease caused by salmonella typhi. On 07-Apr-2024, two days after the first dose, the patient took the second dose of Vivotif (batch number: unknown) at an unknown dose, via oral use. On 09-Apr-2024, four days after the first dose, the patient took the third dose of Vivotif (batch number: unknown) at an unknown dose, via oral use. As reported, patient was taking the medication and got sick with COVID, had third dose yesterday morning, already feeling feverish at that time, but the patient didn't know whether to take the dose or not, so the patient took his dose yesterday, feeling much better, patient says hasn't had a fever since last night. On an unspecified date, the patient tested positive to Covid-19 and the patient had some mild congestion, cough and no other symptoms. At the time of the initial report, the outcome of the event COVID-19 was unknown. The reporter assessed the event COVID-19 as non-serious and causality as possible for the event COVID-19.; Reporter's Comments: A 54-year-old male patient tested positive to Covid-19 after the patient took the third dose of Vivotif for immunization against disease caused by salmonella typhi. COVID-19 is unlisted and unexpected for Vivotif according to the CCDS v8 and USPI. The patient's medical history and concomitant medication details were not provided. The outcome was unknown. Considering the nature of the event, COVID-19 has been considered as not related to the suspect vaccine, but to an infection. This case is considered as non-serious.; Sender's Comments: A 54-year-old male patient tested positive to Covid-19 after the patient took the third dose of Vivotif for immunization against disease caused by salmonella typhi. COVID-19 is unlisted and unexpected for Vivotif according to the CCDS v8 and USPI. The patient's medical history and concomitant medication details were not provided. The outcome was unknown. Considering the nature of the event, COVID-19 has been considered as not related to the suspect vaccine, but to an infection. This case is considered as non-serious.
Comments: None.
Test Name: Covid; Result Unstructured Data: Positive; Comments: /